Investors

Investor Relations

Akebia Therapeutics

Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.

We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.

OUR MEDICINE

RESEARCH & DEVELOPMENT

Press Releases

November 1, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 1, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

October 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

VIEW ALL PRESS RELEASES

Events & Presentations

November 7, 2024 at 8:00 AM EST

Akebia’s Third Quarter 2024 Financial Results

September 9, 2024 at 10:30 AM EDT

H.C. Wainwright 26th Annual Global Investment Conference

September 6, 2024 at 9:30 AM EDT

Wells Fargo 2024 Healthcare Conference

VIEW ALL EVENTS

Data Presentations

Presented at ASN Kidney Week 2021

Comprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials

Presented at ASN Kidney Week 2021

Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis

Presented at ASN Kidney Week 2021

Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia Due to CKD

VIEW ALL DATA PRESENTATIONS

Volume:

Today’s Open:

Previous Close:

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax